Dosage, effectiveness, and safety of sertraline treatment for posttraumatic stress disorder in a Japanese clinical setting: a retrospective study

Table 6 Logistic regression analysis: at least one treatment augmentation vs. no treatment augmentation

Factor	d.f.	Chi-Square statistic	p-value	Odds ratio estimates
Factor	d.f.	Chi-Square statistic	p-value		Point estimate	95% C.I.
Age	1	0.40	0.526		1.01	0.97	1.05
Duration of disease	1	0.04	0.836		1.00	0.98	1.03
Baseline CGI-S	1	0.22	0.638		1.11	0.73	1.69
Concurrent psychiatric disease at baseline	2	0.46	0.793	Depression or Dysthymic disorder vs. None	1.35	0.49	3.76
Concurrent psychiatric disease at baseline	2	0.46	0.793	Other Psychiatric disease vs. None	1.54	0.40	5.94
Traumatic events	3	11.54	0.009	Both Physical and sexual assault vs. Neither	1.43	0.35	5.75
				No sexual assault vs. Neither	0.57	0.19	1.64
				No physical assault vs. Neither	3.80	1.03	14.06

d.f. Degree of freedom, C.I. Confidence interval
No sexual assault: patients experienced traumatic events including physical assault, but no sexual assault
No physical assault: patients experienced traumatic events including sexual assault, but no physical assault

ISSN: 1471-244X